Blood Pressure Disorders Drug Development Pipeline Review, 2018

  • ID: 4618140
  • Report
  • 213 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Japan Tobacco Inc
  • Novartis AG
  • Sanofi
  • MORE

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in the body and the condition of the kidneys, nervous system, and blood vessels.

Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically do not occur until high blood pressure has reached a severe stage. There are 253 products in development for this indication.

PAH is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). There are 92 products in development for this indication.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Pipeline activity is much lower for hypotension than for hypertension or PAH with only seven products in development for this indication.
Molecular targets acted on by products in development for blood pressure disorders include angiotensin receptors, tyrosine protein kinases and phosphodiesterases.

This report “Blood Pressure Disorders Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.

Scope

  • Which companies are the most active within the pipeline for blood pressure disorders?
  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Bristol-Myers Squibb Co
  • Eli Lilly and Co
  • Japan Tobacco Inc
  • Novartis AG
  • Sanofi
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 Blood Pressure Disorder Report Coverage
2.2 Hypertension - Overview
2.3 Hypotension - Overview
2.4 Pulmonary Arterial Hypertension - Overview

3 Therapeutics Development

3.1 Hypertension
3.2 Hypotension
3.3 Pulmonary Arterial Hypertension

4 Therapeutics Assessment

4.1 Hypertension
4.2 Hypotension
4.3 Pulmonary Arterial Hypertension

5 Companies Involved in Therapeutics Development

5.1 Hypertension
5.2 Hypotension
5.3 Pulmonary Arterial Hypertension

6 Dormant Projects

6.1 Hypertension
6.2 Hypotension
6.3 Pulmonary Arterial Hypertension

7 Discontinued Products

7.1 Hypertension
7.2 Pulmonary Arterial Hypertension

8 Product Development Milestones

8.1 Hypertension
8.2 Hypotension
8.3 Pulmonary Arterial Hypertension

9 Appendix

1.1 List of Tables

Table 1: Number of Products under Development for Hypertension
Table 2: Number of Products under Development by Companies Hypertension
Table 3: Number of Products under Development by Universities/Institutes Hypertension
Table 4: Products under Development by Companies Hypertension
Table 5: Products under Development by Universities/Institutes Hypertension
Table 6: Number of Products under Development for Hypotension
Table 7: Number of Products under Development by Companies Hypotension
Table 8: Products under Development by Companies Hypotension
Table 9: Number of Products under Development for Pulmonary Arterial Hypertension
Table 10: Number of Products under Development by Companies Pulmonary Arterial Hypertension
Table 11: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension
Table 12: Products under Development by Companies Pulmonary Arterial Hypertension
Table 13: Products under Development by Universities/Institutes Pulmonary Arterial Hypertension
Table 14: Number of Products by Stage and Target Hypertension
Table 15: Number of Products by Stage and Mechanism of Action Hypertension
Table 16: Number of Products by Stage and Route of Administration Hypertension
Table 17: Number of Products by Stage and Molecule Type Hypertension
Table 18: Number of Products by Stage and Target Hypotension
Table 19: Number of Products by Stage and Mechanism of Action Hypotension
Table 20: Number of Products by Stage and Route of Administration Hypotension
Table 21: Number of Products by Stage and Molecule Type Hypotension
Table 22: Number of Products by Stage and Target Pulmonary Arterial Hypertension
Table 23: Number of Products by Stage and Mechanism of Action Pulmonary Arterial Hypertension
Table 24: Number of Products by Stage and Route of Administration Pulmonary Arterial Hypertension
Table 25: Number of Products by Stage and Molecule Type Pulmonary Arterial Hypertension
Table 26: Hypertension - Pipeline by A1M Pharma AB
Table 27: Hypertension - Pipeline by Acceleron Pharma Inc
Table 28: Hypertension - Pipeline by Ache Laboratorios Farmaceuticos SA
Table 29: Hypertension - Pipeline by Actelion Pharmaceuticals Ltd
Table 30: Hypertension - Pipeline by Aerogen Ltd
Table 31: Hypertension - Pipeline by Anavex Life Sciences Corp
Table 32: Hypertension - Pipeline by AnGes Inc
Table 33: Hypertension - Pipeline by Arena Pharmaceuticals Inc
Table 34: Hypertension - Pipeline by Ascendia Pharmaceuticals LLC
Table 35: Hypertension - Pipeline by Ascendis Pharma A/S
Table 36: Hypertension - Pipeline by AVEO Pharmaceuticals Inc
Table 37: Hypertension - Pipeline by Bayer AG
Table 38: Hypertension - Pipeline by Bial - Portela & Ca SA
Table 39: Hypertension - Pipeline by Bioblue Technologies Inc
Table 40: Hypertension - Pipeline by Biogen Inc
Table 41: Hypertension - Pipeline by Biolab Farmaceutica Ltda
Table 42: Hypertension - Pipeline by BioRestorative Therapies Inc
Table 43: Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd
Table 44: Hypertension - Pipeline by Bristol-Myers Squibb Co
Table 45: Hypertension - Pipeline by Camurus AB
Table 46: Hypertension - Pipeline by Capricor Therapeutics Inc
Table 47: Hypertension - Pipeline by Celsion Corp
Table 48: Hypertension - Pipeline by Celtaxsys Inc
Table 49: Hypertension - Pipeline by Chiesi Farmaceutici SpA
Table 50: Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp
Table 51: Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd
Table 52: Hypertension - Pipeline by CJ HealthCare Corp
Table 53: Hypertension - Pipeline by Complexa Inc
Table 54: Hypertension - Pipeline by Corion Biotech Srl

1.2 List of Figures

Figure 1: Number of Products under Development for Hypertension
Figure 2: Number of Products under Development by Companies Hypertension
Figure 3: Number of Products under Development by Universities/Institutes Hypertension
Figure 4: Number of Products under Development for Hypotension
Figure 5: Number of Products under Development by Companies Hypotension
Figure 6: Number of Products under Development for Pulmonary Arterial Hypertension
Figure 7: Number of Products under Development by Companies Pulmonary Arterial Hypertension
Figure 8: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension
Figure 9: Number of Products by Top 10 Targets Hypertension
Figure 10: Number of Products by Stage and Top 10 Targets Hypertension
Figure 11: Number of Products by Top 10 Mechanism of Actions Hypertension
Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions Hypertension
Figure 13: Number of Products by Top 10 Routes of Administration Hypertension
Figure 14: Number of Products by Stage and Top 10 Routes of Administration Hypertension
Figure 15: Number of Products by Top 10 Molecule Types Hypertension
Figure 16: Number of Products by Stage and Top 10 Molecule Types Hypertension
Figure 17: Number of Products by Targets Hypotension
Figure 18: Number of Products by Stage and Targets Hypotension
Figure 19: Number of Products by Mechanism of Actions Hypotension
Figure 20: Number of Products by Stage and Mechanism of Actions Hypotension
Figure 21: Number of Products by Routes of Administration Hypotension
Figure 22: Number of Products by Stage and Routes of Administration Hypotension
Figure 23: Number of Products by Molecule Types Hypotension
Figure 24: Number of Products by Stage and Molecule Types Hypotension
Figure 25: Number of Products by Top 10 Targets Pulmonary Arterial Hypertension
Figure 26: Number of Products by Stage and Top 10 Targets Pulmonary Arterial Hypertension
Figure 27: Number of Products by Top 10 Mechanism of Actions Pulmonary Arterial Hypertension
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions Pulmonary Arterial Hypertension
Figure 29: Number of Products by Routes of Administration Pulmonary Arterial Hypertension
Figure 30: Number of Products by Stage and Routes of Administration Pulmonary Arterial Hypertension
Figure 31: Number of Products by Top 10 Molecule Types Pulmonary Arterial Hypertension
Figure 32: Number of Products by Stage and Top 10 Molecule Types Pulmonary Arterial Hypertension

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • A1M Pharma AB
  • Acceleron Pharma Inc
  • Ache Laboratorios Farmaceuticos SA
  • Actelion Pharmaceuticals Ltd
  • Aerogen Ltd
  • Anavex Life Sciences Corp
  • AnGes Inc
  • Arena Pharmaceuticals Inc
  • Ascendia Pharmaceuticals LLC
  • Ascendis Pharma A/S
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BCO Pharma Ltd
  • Bial - Portela & Ca SA
  • Bioblue Technologies Inc
  • Biogen Inc
  • Biolab Farmaceutica Ltda
  • BioRestorative Therapies Inc
  • Boryung Pharmaceutical Co Ltd
  • Bristol-Myers Squibb Co
  • Camurus AB
  • Capricor Therapeutics Inc
  • Celsion Corp
  • Celtaxsys Inc
  • Cerecor Inc
  • Chiesi Farmaceutici SpA
  • Chong Kun Dang Pharmaceutical Corp
  • Chugai Pharmaceutical Co Ltd
  • CJ HealthCare Corp
  • Complexa Inc
  • Corion Biotech Srl
  • Cumberland Pharmaceuticals Inc
  • D. Western Therapeutics Institute Inc
  • Daewon Pharm Co Ltd
  • Daewoong Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • Denovo Biopharma LLC
  • Eli Lilly and Co
  • Esperion Therapeutics Inc
  • FunPep Co Ltd
  • Galectin Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • H. Lundbeck AS
  • HanAll Biopharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Hypotension
  • Idorsia Pharmaceutical Ltd
  • Ildong Pharmaceutical Co Ltd
  • Innopharmax Inc
  • Insmed Inc
  • Insys Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Japan Tobacco Inc
  • Jeil Pharmaceutical Co Ltd
  • Johnson & Johnson
  • KBP BioSciences Co Ltd
  • La Jolla Pharmaceutical Company
  • Leading BioSciences Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Les Laboratoires Servier SAS
  • LG Chem Ltd
  • LinXis BV
  • Liquidia Technologies Inc
  • MannKind Corp
  • Marina Biotech Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • N4 Pharma Plc
  • Nippon Shinyaku Co Ltd
  • Nissan Chemical Industries Ltd
  • Northern Therapeutics Inc
  • Novartis AG
  • Omeros Corp
  • Orion Corporation
  • Peloton Therapeutics Inc
  • Pfizer Inc
  • PhaseBio Pharmaceuticals Inc
  • Pulmokine Inc
  • Pulmonary Arterial Hypertension
  • Quantum Genomics SA
  • Reata Pharmaceuticals Inc
  • Relief Therapeutics Holding AG
  • Relypsa Inc
  • Renova Therapeutics Inc
  • Respira Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • rEVO Biologics Inc
  • Roivant Sciences Ltd
  • Rottapharm Biotech Srl
  • Sanofi
  • Sarfez Pharmaceuticals Inc
  • Serodus ASA
  • Shanghai Pharmaceutical Co Ltd
  • SJT Molecular Research SL
  • SteadyMed Therapeutics Inc
  • Suda Pharmaceuticals Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Takeda Pharmaceutical Co Ltd
  • Target Medicals LLC
  • The Medicines Company
  • Theracos Inc
  • Theravance Biopharma Inc
  • Toray Industries Inc
  • TrioxBio Inc
  • United Therapeutics Corp
  • Vascular BioSciences
  • VG Life Sciences Inc
  • Vicore Pharma AB
  • Vivus Inc
  • XuanZhu Pharma Co Ltd
  • Yuhan Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4618140
Adroll
adroll